• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Scholar Rock Holding Corp (NQ: SRRK )

    8.130 -0.200 (-2.40%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 707,845
    Open 8.290
    Bid (Size) 8.150 (1)
    Ask (Size) 8.750 (2)
    Prev. Close 8.330
    Today's Range 8.060 - 8.560
    52wk Range 5.930 - 21.17
    Shares Outstanding 79,754,065
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal
    From Scholar Rock
    Via Business Wire
    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Scholar Rock
    Via Business Wire

    Performance

    YTD
    -53.54%
    -53.54%
    1 Month
    -14.24%
    -14.24%
    3 Month
    -51.58%
    -51.58%
    6 Month
    -53.54%
    -53.54%
    1 Year
    +10.01%
    +10.01%

    More News

    Read More
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting
    From Scholar Rock
    Via Business Wire
    Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
    From Scholar Rock
    Via Business Wire
    Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity
    From Scholar Rock
    Via Business Wire
    Scholar Rock to Participate in Upcoming Investor Conferences
    From Scholar Rock
    Via Business Wire
    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Scholar Rock
    Via Business Wire
    Scholar Rock to Host Investor Day on May 22, 2024
    From Scholar Rock
    Via Business Wire
    SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q1 2024
    Via InvestorPlace
    Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress
    From Scholar Rock
    Via Business Wire
    3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
    Via InvestorPlace
    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Scholar Rock
    Via Business Wire
    Scholar Rock Is A Potential M&A Target, Its Exploration of Obesity Market Garners Interest: Analyst
    Via Benzinga
    SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q4 2023
    Via InvestorPlace
    Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress
    From Scholar Rock
    Via Business Wire
    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Scholar Rock, Inc.
    Via Business Wire
    NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Scholar Rock to Participate in Upcoming Investor Conferences
    From Scholar Rock
    Via Business Wire
    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Scholar Rock
    Via Business Wire
    Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer
    From Scholar Rock
    Via Business Wire
    Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management
    From Scholar Rock
    Via Business Wire
    Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia
    From Scholar Rock
    Via Business Wire
    Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity
    From Scholar Rock
    Via Business Wire
    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Scholar Rock
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.